文献速递骨软组织肉瘤与黑色素瘤

瑞戈非尼在经化疗和帕唑帕尼治疗的非脂肪细胞性软组织肉瘤中的双盲安慰剂对照随机II期试验

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
PubMed 文献 · Eur J Cancer · 2020-01-06

该双盲随机II期试验纳入37例经化疗和帕唑帕尼治疗后的转移性非脂肪细胞性软组织肉瘤患者,瑞戈非尼组18例、安慰剂组19例。结果显示瑞戈非尼显著改善无进展生存期(校正HR=0.33,95%CI 0.15-0.74,p=0.0007,中位PFS 2.1 vs 1.1个月),并观察到总生存期接近显著的获益(校正HR=0.49,95%CI 0.23-1.06,p=0.007,中位OS 17.8 vs 8.2个月)。

要点

  • 瑞戈非尼较安慰剂显著延长经化疗和帕唑帕尼治疗后的非脂肪细胞性STS患者的PFS。
  • 总生存期获益接近统计学显著,尽管安慰剂组允许交叉。
  • 常见≥3级不良事件包括淋巴细胞减少、腹泻、呼吸困难、皮肤毒性、高血压和转氨酶升高。

核心结论

  • 瑞戈非尼在经重度治疗的非脂肪细胞性软组织肉瘤患者中显示出有意义的临床抗肿瘤活性。

研究设计与样本

  • 双盲、安慰剂对照、多中心、比较性随机II期试验,纳入37例组织学证实的晚期不可手术软组织肉瘤患者,随机分配至瑞戈非尼组18例或安慰剂组19例。

主要发现

  • 瑞戈非尼组与安慰剂组的中位PFS分别为2.1个月和1.1个月,校正HR=0.33(95%CI 0.15-0.74),p=0.0007。
  • 瑞戈非尼组与安慰剂组的中位OS分别为17.8个月和8.2个月,校正HR=0.49(95%CI 0.23-1.06),p=0.007。

关键数值与推荐

  • 主要终点为盲态独立中心审查基于RECIST标准的无进展生存期,在意向治疗人群分析。
  • 研究设计需24个事件以达到90%把握度,HR=0.33(中位PFS 3.6 vs 1.2个月),单侧α=0.1。
  • 交叉前最常见的≥3级不良事件:淋巴细胞减少(瑞戈非尼组5例 vs 安慰剂组1例)、腹泻(4 vs 0)、呼吸困难(3 vs 1)、皮肤毒性(3 vs 0)、动脉高血压(2 vs 0)、转氨酶升高(2 vs 0)。

临床怎么用

  • 对于经化疗和帕唑帕尼治疗后的非脂肪细胞性软组织肉瘤患者,瑞戈非尼可考虑作为治疗选择。
  • 治疗期间需监测淋巴细胞减少、腹泻、呼吸困难、皮肤毒性、高血压和转氨酶升高等不良事件。

局限性

  • 样本量较小(37例),为II期探索性研究。
  • 安慰剂组允许交叉可能影响总生存期分析。
  • 随访时间中位27.2个月(95%CI 24.4-未达到),长期结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic soft tissue sarcomas (STSs) management remains an unmet medical need. We assessed the activity and safety of regorafenib in patients with metastatic non-adipocytic STS who were previously treated with both chemotherapy and pazopanib. PATIENTS AND METHODS: This double-blind, placebo-controlled, multicenter comparative randomized phase II trial included patients with histologically proven advanced and inoperable STS. Patients receiving placebo were offered optional cross-over for centrally confirmed disease progression. Primary end-point was centrally reviewed Response Evaluation Criteria in Solid Tumours-based progression-free survival (PFS), analysed on the intent-to-treat data set. In total, 24 events were required for 90% power, hazard ratio (HR) = 0.33 (median PFS, 3.6 versus 1.2 months), and 1-sided α = 0.1 (ClinicalTrials.gov, NCT01900743). RESULTS: From December 2015 to October 2017, 37 patients were randomized; 18 to regorafenib and 19 to placebo. Thirteen patients assigned to placebo switched to regorafenib after progression. Median follow-up was 27.2 months (95% confidence interval [CI]: 24.4-not reached). We observed a significant PFS benefit of regorafenib compared with placebo (adjusted HR = 0.33; 95% CI: 0.15-0.74; p = 0.0007 median PFS = 2.1 versus 1.1 months, respectively), and a large and nearly significant overall survival (OS) benefit despite the cross-over (adjusted HR = 0.49; 95% CI: 0.23-1.06; p = 0.007; median OS = 17.8 versus 8.2 months). Before cross-over, the most common grade III or higher adverse events were lymphopenia (5 versus 1, respectively), diarrhoea (4 versus 0), dyspnoea (3 versus 1), skin toxicity (3 versus 0), arterial hypertension (2 versus 0), and increased transaminases (2 versus 0). CONCLUSION: The present study demonstrated a meaningful clinical anti-tumour activity with regorafenib in heavily pre-treated patients with non-adipocytic STS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Penel N, Mir O, Wallet J, et al. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. Eur J Cancer. 2020. PMID: 31918233. doi:10.1016/j.ejca.2019.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。